ICER says Luxturna is not cost-effective

In an evidence report published Friday, the Institute for Clinical and Economic Review said vision loss drug Luxturna voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE) needs substantial discounts to be cost-effective.

The institute said while clinical evidence on Luxturna provides high certainty of

Read the full 422 word article

User Sign In